Dachaigh › Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil › Massachusetts › Boston
Sgrùdaidhean clionaigeach Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil ann an Boston, MA
Tha 40 sgrùdaidhean airson Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil a’ lorg phàirtichean aig làraichean ann agus timcheall air Boston (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
A’ fastadhÌre 1
- Massachusetts General Hospital, Boston
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
A’ fastadhÌre 2/3
- Site #0131, Boston
- Site#0101, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A’ fastadhÌre 1
- Exelixis Clinical Site #7, Boston
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
A’ fastadhÌre 3
- Boston Medical Center, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
A’ fastadhÌre 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
A’ fastadhÌre 1
- Research Site, Boston
- Research Site, Boston
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
A’ fastadhÌre 3
- Dana Farber Cancer Institute, Boston
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
A’ fastadhÌre 1/2
- Dana Farber Cancer Institute, Boston
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
A’ fastadhÌre 3
- Boston Medical Center, Boston
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
A’ fastadhÌre 1
- Boston Medical Center, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
A’ fastadhÌre 1/2
- Tufts Medical Center, Boston
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
A’ fastadhÌre 2
- Tufts Medical Center, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
A’ fastadhÌre 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
A’ fastadhÌre 2
- Tufts Medical Center, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
A’ fastadhÌre 1
- Massachusetts General Hospital, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
A’ fastadhSgrùdadh amharc
- Dana Farber Cancer Institute, Boston
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
A’ fastadhÌre 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
A’ fastadhÌre 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
A’ fastadhÌre 2
- Boston Medical Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
A’ fastadhÌre 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
PDT For Induction Therapy For Head And Neck Cancer
A’ fastadhÌre 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A’ fastadhÌre 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- agus 2 a bharrachd
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
A’ fastadhÌre 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
A’ fastadhÌre 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
A’ fastadhÌre 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Dana-Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
A’ fastadhÌre 1
- Dana Farber Cancer Institute, Boston
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
A’ fastadhÌre 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
A’ fastadhÌre 1 tràth
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
A’ fastadhÌre 1/2
- Dana Farber Cancer Institute, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
A’ fastadhÌre 1
- Dana Farber/Partners Cancer Care Inc, Boston
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
A’ fastadhSgrùdadh amharc
- Massachusetts Eye and Ear, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
A’ fastadhÌre 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
A’ fastadhÌre 2
- Dana Farber Cancer Institute, Boston
Sgrùdaidhean Carcinoma Cealla Sgamach a' Chinn agus a' Mhuineil ann am bailtean eile
- Houston, TX47 sgrùdaidhean
- Los Angeles, CA42 sgrùdaidhean
- New York City, NY39 sgrùdaidhean
- Nashville, TN39 sgrùdaidhean
- St. Louis, MO28 sgrùdaidhean
- Arlington, VA26 sgrùdaidhean
- Philadelphia, PA26 sgrùdaidhean
- Chicago, IL26 sgrùdaidhean
- Atlanta, GA24 sgrùdaidhean
- San Antonio, TX22 sgrùdaidhean
- New Haven, CT22 sgrùdaidhean
- Pittsburgh, PA22 sgrùdaidhean
Sgrùdaidhean eile ann an Boston
- Aillse a' bhroilleach112 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag90 sgrùdaidhean
- Aillse (gach seòrsa)85 sgrùdaidhean
- Ailse metastatach63 sgrùdaidhean
- Aillse colorectal63 sgrùdaidhean
- Ailseachadh nan Sgamhan62 sgrùdaidhean
- Cancer Ovarian61 sgrùdaidhean
- Aillse Prostata59 sgrùdaidhean
- Depression52 sgrùdaidhean
- Ailse Endometrial50 sgrùdaidhean
- Fàilligeadh a' Chridhe44 sgrùdaidhean
- Leukemia myeloid geur44 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.